These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 36997057)

  • 1. ECM2, a prognostic biomarker for lower grade glioma, serves as a potential novel target for immunotherapy.
    Cheng X; Liu Z; Liang W; Zhu Q; Wang C; Wang H; Zhang J; Li P; Gao Y
    Int J Biochem Cell Biol; 2023 May; 158():106409. PubMed ID: 36997057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
    Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
    Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
    Lu J; Peng Y; Huang R; Feng Z; Fan Y; Wang H; Zeng Z; Ji Y; Wang Y; Wang Z
    BMC Cancer; 2021 Jun; 21(1):723. PubMed ID: 34162355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of DNA methylation-regulated WEE1 with potential implications in prognosis and immunotherapy for low-grade glioma.
    Zhong WJ; Zhang LZ; Yue F; Yuan L; Zhang Q; Li X; Lin L
    Cancer Biomark; 2024; 40(3-4):297-317. PubMed ID: 39213054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
    Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
    Front Immunol; 2022; 13():899710. PubMed ID: 35677036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selenoprotein GPX1 is a prognostic and chemotherapy-related biomarker for brain lower grade glioma.
    Chen X; Fu G; Li L; Zhao Q; Ke Z; Zhang R
    J Trace Elem Med Biol; 2022 Dec; 74():127082. PubMed ID: 36155420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EFNA1 is a potential key gene that correlates with immune infiltration in low-grade glioma.
    Hao YP; Wang WY; Qiao Q; Li G
    Medicine (Baltimore); 2021 Jun; 100(22):e26188. PubMed ID: 34087884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High
    Li J; Wang S; He Q; Lin F; Tao C; Ding Y; Wang J; Zhao J; Wang W
    Brain Sci; 2023 May; 13(6):. PubMed ID: 37371331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SYT16 is a prognostic biomarker and correlated with immune infiltrates in glioma: A study based on TCGA data.
    Chen J; Wang Z; Wang W; Ren S; Xue J; Zhong L; Jiang T; Wei H; Zhang C
    Int Immunopharmacol; 2020 Jul; 84():106490. PubMed ID: 32289666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Systematic Landscape of Nectin Family and Nectin-Like Molecules: Functions and Prognostic Value in Low Grade Glioma.
    Han Y; Zou C; Zhu C; Liu T; Shen S; Cheng P; Cheng W; Wu A
    Front Genet; 2021; 12():718717. PubMed ID: 34925438
    [No Abstract]   [Full Text] [Related]  

  • 11. DNMT3A promotes glioma growth and malignancy via TNF-α/NF-κB signaling pathway.
    Su X; Liu J; Tu Z; Ji Q; Li J; Liu F
    Transl Cancer Res; 2024 Apr; 13(4):1786-1806. PubMed ID: 38737693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Potential of METTL7B in Glioma.
    Fu R; Luo X; Ding Y; Guo S
    Neuroimmunomodulation; 2022; 29(3):186-201. PubMed ID: 35034026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Immune-Related lncRNA SBF2-AS1 in Diffuse Lower-Grade Glioma.
    Zhang Q; Liu XJ; Li Y; Ying XW; Chen L
    Technol Cancer Res Treat; 2021; 20():15330338211011966. PubMed ID: 34159865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ABCD3 is a prognostic biomarker for glioma and associated with immune infiltration: A study based on oncolysis of gliomas.
    Li J; Zhang Y; Qu Z; Ding R; Yin X
    Front Cell Infect Microbiol; 2022; 12():956801. PubMed ID: 35959373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
    Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
    Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positive regulators of T cell functions as predictors of prognosis and microenvironment characteristics of low-grade gliomas.
    Li Y; Feng Y; Luo F; Peng G; Li Y
    Front Immunol; 2022; 13():1089792. PubMed ID: 36726969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TGF-β Score based on
    Zhang W; Yan Z; Zhao F; He Q; Xu H
    Recent Pat Anticancer Drug Discov; 2024; 19(5):610-621. PubMed ID: 37718518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrated Analysis Reveals Prognostic Value and Immune Correlates of CD86 Expression in Lower Grade Glioma.
    Qiu H; Tian W; He Y; Li J; He C; Li Y; Liu N; Li J
    Front Oncol; 2021; 11():654350. PubMed ID: 33954112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
    Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
    Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.